http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-090941
The primary objective of this study is to confirm the efficacy of CS-8958 (given once weekly, two times in total) to prevent influenza virus infection among household contacts of influenza-infected cases. For safety evaluation, between-group comparisons will be made with regard to incidence of adverse events and other safety measures.
*************In a secondary objective, the optimum dosage of CS-8958 for this indication will be estimated based on the efficacy and safety***************
- Forums
- ASX - By Stock
- BTA
- Ann: Phase III prophylaxis trial for CS-8958
Ann: Phase III prophylaxis trial for CS-8958 , page-14
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online